Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment

Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In additi...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 620187
Main Authors Sarabia De Ardanaz, Luis, Andreu-Ubero, Jose M., Navidad-Fuentes, Miriam, Ferrer-González, Miguel Ángel, Ruíz del Valle, Victor, Salcedo-Bellido, Inmaculada, Barrios-Rodríguez, Rocío, Cáliz-Cáliz, Rafael, Requena, Pilar
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 01.07.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In addition, the mean differences between discharged and deceased patients in laboratory parameters measured before and 3, 6 and 9 days after TCZ administration were estimated with weighted generalized estimation equations. The variables associated with time to death were immunosuppression (Hazard Ratio-HR 3.15; 95% confidence interval-CI 1.17, 8.51), diabetes mellitus (HR 2.63; 95% CI 1.23–5.64), age (HR 1.05; 95% CI 1.02–1.09), days since diagnosis until TCZ administration (HR 1.05, 95% CI 1.00–1.09), and platelets (HR 0.27; 95% CI: 0.11, 0.69). In the post-TCZ analysis and compared to discharged patients, deceased patients had more lactate dehydrogenase ( p = 0.013), troponin I ( p = 0.013), C-reactive protein ( p = 0.013), neutrophils ( p = 0.024), and fewer platelets ( p = 0.013) and lymphocytes ( p = 0.013) as well as a lower average PaO 2 /FiO 2 ratio. In conclusion, in COVID-19 diagnosed patients receiving TCZ, early treatment decreased the risk of death, while age, some comorbidities and baseline lower platelet counts increased that risk. After TCZ administration, lower platelet levels were again associated with mortality, together with other laboratory parameters.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors share senior authorship
This article was submitted to Drugs Outcomes Research and Policies, a section of the journal Frontiers in Pharmacology
Reviewed by: Eliseo Albert, Hospital Clínico Universitario de Valencia, Spain
Yojana Gokhale, Lokmanya Tilak Municipal General Hospital, India
Cristian Deana, Azienda Sanitaria Universitaria Integrata di Udine, Italy
Edited by: Rafael Maldonado, Pompeu Fabra University, Spain
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2021.620187